Impact BioMedical Inc.
IBO
IBOImpact BioMedical Inc.
New York Stock Exchange Arca0.45
USD
-0.02
(-4.76%)
CIK
0001834105
ISIN
US45259L2051
CUSIP
45259L205
Return %
Stock
S&P500
1Y
-83.21
9.99
3Y
-99.88
59.68
5Y
-99.88
94.43
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mr. Frank D. Heuszel Esq., J.D.
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1400 Broadfield Blvd. Houston TX United States of America 77084
- CIK
- 0001834105
- Website
- impactbiomedinc.com
- Similar Companies
- Business
- Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. The company was incorporated in 2018 and is based in Houston, Texas.
Company News
Impact Biomedical Inc. Announcement Stock Activity/Pricing
Impact BioMedical Inc. to Present at The Microcap Conference
Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease
Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates
Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue
Impact BioMedical Inc. Announces the Closing of its Initial Public Offering
Impact BioMedical Inc. Announces Pricing of Initial Public Offering